Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130227 | 1.00 | NAMPT (0.39) | NAMPTMAPK1MEN1KMT2ACCNT1 | |
| SCHEMBL7117906 | 0.87 | QDPR (0.39) | NAMPTQDPR | |
| SCHEMBL7508337 | 0.87 | QDPR (0.39) | NAMPTQDPR | |
| SCHEMBL7125301 | 0.84 | NAMPT (0.49) | NAMPT | |
| SCHEMBL7126216 | 0.84 | NAMPT (0.49) | NAMPT | |
| SCHEMBL7118426 | 0.82 | CCNT1 (0.39) | NAMPTCCNT1CDK9 | |
| SCHEMBL7124582 | 0.76 | QDPR (0.40) | NAMPTQDPR | |
| SCHEMBL7122724 | 0.76 | QDPR (0.40) | NAMPTQDPR | |
| SCHEMBL7123785 | 0.74 | MEN1 (0.41) | NAMPTMAPK1MEN1KMT2ACCNT1 | |
| SCHEMBL8446917 | 0.74 | MEN1 (0.39) | NAMPTMAPK1MEN1KMT2ACCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | SYNGENTA LIMITED (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-0912561-B1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-6350775-B1 | AGAINST GRAMPOSITIVE BACTERIA | ZENECA LIMITED (GB) | 2002-02-26 | — | — | US | disclosed |
| US-6110936-A | A BACTERICIDE TREATING A BACTERIAL INFECTION IN A WARM BLOODED ANIMAL | ZENECA LIMITED (GB) | 2000-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166684-A1 | 3-phenyl-furan-(5H)-2-one and dihydrofuran-2-one derivatives as antibacterial agents | CBR1, CBR3, CYP8B1 | NAMPT 4578/4885MAPK1 2046/4885MEN1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.